Aquestive Therapeutics, Inc. Investing Cash Flow
Aquestive Therapeutics, Inc. (AQST) reported Investing Cash Flow of -$264.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Aquestive Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$212.00K.
- Aquestive Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$52.00K.
- Aquestive Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$85.00K.
- Aquestive Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$235.00K.
- Aquestive Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$562.00K.
- Aquestive Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$159.00K.
- Aquestive Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$995.00K.
- Aquestive Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$2.52M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$212.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$264.00K 10-Q · filed 2026-08-11 | -$349.00K derived: sum of 3 quarters · filed 2026-08-11 | -$584.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$52.00K 10-Q · filed 2026-05-13 | -$137.00K derived: sum of 2 quarters · filed 2026-05-13 | -$372.00K derived: sum of 3 quarters · filed 2026-05-13 | -$479.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$320.00K derived: sum of 2 quarters · filed 2026-03-04 | -$427.00K derived: sum of 3 quarters · filed 2026-08-11 | -$562.00K 10-K · filed 2026-03-04 |
| 2025-09-30 | -$235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$342.00K derived: sum of 2 quarters · filed 2026-08-11 | -$477.00K 10-Q · filed 2025-11-05 | -$492.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$107.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$242.00K 10-Q · filed 2026-08-11 | -$257.00K derived: sum of 3 quarters · filed 2026-08-11 | -$337.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$135.00K 10-Q · filed 2026-05-13 | -$150.00K derived: sum of 2 quarters · filed 2026-05-13 | -$230.00K derived: sum of 3 quarters · filed 2026-05-13 | -$265.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$95.00K derived: sum of 2 quarters · filed 2026-03-04 | -$130.00K derived: sum of 3 quarters · filed 2026-03-04 | -$159.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | -$80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$115.00K derived: sum of 2 quarters · filed 2025-11-05 | -$144.00K 10-Q · filed 2025-11-05 | -$160.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$64.00K 10-Q · filed 2025-08-11 | -$80.00K derived: sum of 3 quarters · filed 2025-08-11 | -$231.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$29.00K 10-Q · filed 2025-05-12 | -$45.00K derived: sum of 2 quarters · filed 2025-05-12 | -$196.00K derived: sum of 3 quarters · filed 2025-05-12 | -$1.02M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$167.00K derived: sum of 2 quarters · filed 2025-03-05 | -$993.00K derived: sum of 3 quarters · filed 2025-03-05 | -$995.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | -$151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$977.00K derived: sum of 2 quarters · filed 2024-11-04 | -$979.00K 10-Q · filed 2024-11-04 | -$1.00M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | -$826.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$828.00K 10-Q · filed 2024-08-06 | -$854.00K derived: sum of 3 quarters · filed 2024-08-06 | -$2.57M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$2.00K 10-Q · filed 2024-05-07 | -$28.00K derived: sum of 2 quarters · filed 2024-05-07 | -$1.75M derived: sum of 3 quarters · filed 2024-05-07 | -$2.42M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$1.74M derived: sum of 2 quarters · filed 2024-03-05 | -$2.42M derived: sum of 3 quarters · filed 2024-03-05 | -$2.52M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$2.39M derived: sum of 2 quarters · filed 2023-11-06 | -$2.50M 10-Q · filed 2023-11-06 | -$3.03M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$677.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$781.00K 10-Q · filed 2023-08-07 | -$1.31M derived: sum of 3 quarters · filed 2023-08-07 | -$1.40M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | -$104.00K 10-Q · filed 2023-05-02 | -$637.00K derived: sum of 2 quarters · filed 2023-05-02 | -$720.00K derived: sum of 3 quarters · filed 2023-05-02 | -$914.00K derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | -$533.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$616.00K derived: sum of 2 quarters · filed 2023-03-31 | -$810.00K derived: sum of 3 quarters · filed 2023-03-31 | -$913.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$277.00K derived: sum of 2 quarters · filed 2022-11-01 | -$380.00K 10-Q · filed 2022-11-01 | -$616.00K derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | -$194.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$297.00K 10-Q · filed 2022-08-02 | -$533.00K derived: sum of 3 quarters · filed 2022-08-02 | -$571.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | -$103.00K 10-Q · filed 2022-05-04 | -$339.00K derived: sum of 2 quarters · filed 2022-05-04 | -$377.00K derived: sum of 3 quarters · filed 2022-05-04 | -$489.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$236.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$274.00K derived: sum of 2 quarters · filed 2022-03-08 | -$386.00K derived: sum of 3 quarters · filed 2022-03-08 | -$517.00K 10-K · filed 2022-03-08 |
| 2020-09-30 | -$38.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$150.00K derived: sum of 2 quarters · filed 2021-11-02 | -$281.00K 10-Q · filed 2021-11-02 | -$367.00K derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | -$112.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$243.00K 10-Q · filed 2021-08-03 | -$329.00K derived: sum of 3 quarters · filed 2021-08-03 | -$420.00K derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | -$131.00K 10-Q · filed 2021-05-04 | -$217.00K derived: sum of 2 quarters · filed 2021-05-04 | -$308.00K derived: sum of 3 quarters · filed 2021-05-04 | -$418.00K derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | -$86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$177.00K derived: sum of 2 quarters · filed 2021-03-09 | -$287.00K derived: sum of 3 quarters · filed 2021-03-09 | -$663.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | -$91.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$201.00K derived: sum of 2 quarters · filed 2020-11-04 | -$577.00K 10-Q · filed 2020-11-04 | -$1.07M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | -$110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$486.00K 10-Q · filed 2020-08-04 | -$976.00K derived: sum of 3 quarters · filed 2020-08-04 | -$1.42M derived: sum of 4 quarters · filed 2020-08-04 |
| 2019-03-31 | -$376.00K 10-Q · filed 2020-05-05 | -$866.00K derived: sum of 2 quarters · filed 2020-05-05 | -$1.31M derived: sum of 3 quarters · filed 2020-05-05 | -$1.94M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-31 | -$490.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$938.00K derived: sum of 2 quarters · filed 2020-03-11 | -$1.56M derived: sum of 3 quarters · filed 2020-03-11 | -$1.82M 10-K · filed 2020-03-11 |
| 2018-09-30 | -$448.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$1.07M derived: sum of 2 quarters · filed 2019-11-05 | -$1.33M 10-Q · filed 2019-11-05 | -$1.42M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | -$627.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$886.00K 10-Q · filed 2019-08-06 | -$974.00K derived: sum of 3 quarters · filed 2019-08-06 | -$1.41M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | -$259.00K 10-Q · filed 2019-05-08 | -$347.00K derived: sum of 2 quarters · filed 2019-05-08 | -$780.00K derived: sum of 3 quarters · filed 2019-05-08 | |
| 2017-12-31 | -$88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$521.00K derived: sum of 2 quarters · filed 2019-03-14 | -$2.07M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$433.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | -$1.98M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | -$1.55M 10-Q · filed 2018-09-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |